ATE311903T1 - Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika - Google Patents

Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika

Info

Publication number: ATE311903T1
Authority: AT; Austria
Prior art keywords: oral; agent; target; bioavailability; enhancing
Prior art date: 1995-10-26

Application number

AT96943268T

Other languages

English (en)

Inventor

Samuel Broder

Kenneth L Duchin

Sami Selim

Original Assignee

Ivax Research Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-26

Filing date

1996-10-24

Publication date

2005-12-15

1996-02-29 Priority claimed from US08/608,776 external-priority patent/US5968972A/en

1996-10-24 Application filed by Ivax Research Inc filed Critical Ivax Research Inc

2005-12-15 Application granted granted Critical

2005-12-15 Publication of ATE311903T1 publication Critical patent/ATE311903T1/de

Links

238000000034 method Methods 0.000 title abstract 3
239000003814 drug Substances 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000003795 chemical substances by application Substances 0.000 abstract 12
239000002246 antineoplastic agent Substances 0.000 abstract 2
238000011260 co-administration Methods 0.000 abstract 2
230000002708 enhancing effect Effects 0.000 abstract 2
239000006186 oral dosage form Substances 0.000 abstract 2
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 abstract 1
GNGBSKIQPUCELM-YBAOVNABSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-[(e,2r)-2-methylhex-4-enyl]-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29, Chemical compound CC[C@@H]1NC(=O)[C@H](C[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O GNGBSKIQPUCELM-YBAOVNABSA-N 0.000 abstract 1
ZNVBEWJRWHNZMK-SYOLRUPNSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,2 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O ZNVBEWJRWHNZMK-SYOLRUPNSA-N 0.000 abstract 1
229930105110 Cyclosporin A Natural products 0.000 abstract 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
GNGBSKIQPUCELM-UHFFFAOYSA-N Cyclosporin F Natural products CCC1NC(=O)C(CC(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O GNGBSKIQPUCELM-UHFFFAOYSA-N 0.000 abstract 1
108010036949 Cyclosporine Proteins 0.000 abstract 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
229930012538 Paclitaxel Natural products 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
229940034982 antineoplastic agent Drugs 0.000 abstract 1
229960001265 ciclosporin Drugs 0.000 abstract 1
108010019594 cyclosporin D Proteins 0.000 abstract 1
108010019252 cyclosporin F Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229960003668 docetaxel Drugs 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
229960005420 etoposide Drugs 0.000 abstract 1
229960004125 ketoconazole Drugs 0.000 abstract 1
229960001592 paclitaxel Drugs 0.000 abstract 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)

AT96943268T 1995-10-26 1996-10-24 Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika ATE311903T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US707195P	1995-10-26	1995-10-26
US08/608,776 US5968972A (en)	1995-10-26	1996-02-29	Method for increasing the oral bioactivity of pharmaceutical agents
US08/733,142 US6245805B1 (en)	1995-10-26	1996-10-16	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
PCT/IB1996/001485 WO1997015269A2 (en)	1995-10-26	1996-10-24	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents

Publications (1)

Publication Number	Publication Date
ATE311903T1 true ATE311903T1 (de)	2005-12-15

Family

ID=27358262

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96943268T ATE311903T1 (de)	1995-10-26	1996-10-24	Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika

Country Status (21)

Country	Link
US (6)	US6245805B1 (de)
EP (1)	EP0794794B1 (de)
JP (1)	JP3361102B2 (de)
CN (2)	CN100335123C (de)
AT (1)	ATE311903T1 (de)
AU (1)	AU698142B2 (de)
BR (1)	BR9607066A (de)
CA (1)	CA2205534A1 (de)
CZ (1)	CZ202897A3 (de)
DE (2)	DE69636531T2 (de)
DK (1)	DK0794794T3 (de)
ES (1)	ES2109899T3 (de)
HU (1)	HUP9900457A3 (de)
IL (1)	IL121160A0 (de)
MX (1)	MX9704629A (de)
NO (1)	NO321091B1 (de)
NZ (1)	NZ324801A (de)
PL (2)	PL188281B1 (de)
RU (1)	RU2217135C2 (de)
SK (1)	SK85997A3 (de)
WO (1)	WO1997015269A2 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5439686A (en) *	1993-02-22	1995-08-08	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6395770B1 (en) *	1995-10-26	2002-05-28	Baker Norton Pharmaceuticals, Inc.	Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) *	1995-10-26	2001-06-12	Baker Norton Pharmaceuticals, Inc.	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) *	1995-10-26	2005-11-15	Baker Norton Pharmaceuticals, Inc.	Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
JP2002500667A (ja) *	1997-05-27	2002-01-08	ベーカーノートンファーマシューティカルズインコーポレイテッド	人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物
US8853260B2 (en)	1997-06-27	2014-10-07	Abraxis Bioscience, Llc	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
GB9718903D0 (en)	1997-09-05	1997-11-12	Glaxo Group Ltd	Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU9785698A (en)	1997-10-02	1999-04-27	Microcide Pharmaceuticals, Inc.	Fungal efflux pump inhibitors
US6979456B1 (en)	1998-04-01	2005-12-27	Jagotec Ag	Anticancer compositions
US6352844B1 (en) *	1998-06-29	2002-03-05	Childrens Hospital Los Angeles	Treatment of hyperproliferative disorders
EP1749540B1 (de)	1999-05-17	2010-10-13	Cancer Research Ventures Limited	Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen
EP1479382A1 (de) *	1999-06-18	2004-11-24	IVAX Research, Inc.	Taxane enthaltende orale Pharmazeutische Zusammensetzungen sowie Behandlungsverfahren unter deren Verwendung
RU2236226C2 (ru) *	1999-06-18	2004-09-20	Бейкер Нортон Фармасьютикалз, Инк.	Пероральные фармацевтические композиции, содержащие таксаны, и способы лечения с их применением
GB9920548D0 (en) *	1999-08-31	1999-11-03	Rhone Poulenc Rorer Sa	Treatment of hepatocellular carcinoma
US20020147197A1 (en) *	1999-10-08	2002-10-10	Newman Michael J.	Methods and compositions for enhancing pharmaceutical treatments
RU2002113659A (ru) *	1999-10-27	2004-01-27	Бейкер Нортон Фармасьютикалз, Инк. (Us)	Способ и композиции для перорального введения таксанов больным людям
PL350075A1 (en) *	2000-02-02	2002-11-04	Univ Florida State Res Found	Taxane formulations having improved solubility
US6750246B1 (en)	2000-02-03	2004-06-15	Bristol-Myers Squibb Company	C-4 carbonate taxanes
AU2001236009A1 (en) *	2000-03-02	2001-09-12	Hisamitsu Pharmaceutical Co. Inc.	P-glycoprotein modifier-containing medicinal compositions to be delivered to thelarge intestine
US6362217B2 (en)	2000-03-17	2002-03-26	Bristol-Myers Squibb Company	Taxane anticancer agents
CN1551767A (zh) *	2001-02-19	2004-12-01	��˹��ŵ��	癌症的治疗
US20030144312A1 (en) *	2001-10-30	2003-07-31	Schoenhard Grant L.	Inhibitors of ABC drug transporters in multidrug resistant cancer cells
CA2465886A1 (en) *	2001-11-07	2003-05-15	Kathleen S. Crowley	Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
EP1465618A2 (de) *	2001-12-20	2004-10-13	Bristol-Myers Squibb Company	Pharmazeutische zusammensetzungen oral aktiver taxanderivate mit verbesserter bioverfügbarkeit
JP2006514698A (ja) *	2002-10-30	2006-05-11	スフェリックス，インコーポレイテッド	ナノ粒子生物活性物質
US20050113324A1 (en) *	2003-01-15	2005-05-26	Bondarev Igor E.	Modulation of line-1 reverse transcriptase
US20060014677A1 (en) *	2004-07-19	2006-01-19	Isotechnika International Inc.	Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
PE20060416A1 (es) *	2004-08-03	2006-06-09	Novartis Ag	Composicion de inhibidores de renina e inhibidores de proteinas de efusion
RS50822B (sr) *	2004-10-26	2010-08-31	Pharma Mar S.A., Sociedad Unipersonal	Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
US20070087977A1 (en) *	2004-11-16	2007-04-19	Wendye Robbins	Methods and compositions for treating pain
EP1817023A4 (de) *	2004-11-16	2010-08-18	Limerick Biopharma Inc	Verfahren und zusammensetzungen zur schmerzbehandlung
US9839667B2 (en)	2005-10-14	2017-12-12	Allergan, Inc.	Prevention and treatment of ocular side effects with a cyclosporin
EP3103468B1 (de) *	2005-10-14	2020-07-15	Allergan, Inc.	Prävention von mit arzneimitteln in zusammenhang stehenden keratokonjunctivitis mit cyclosporin
US7745400B2 (en) *	2005-10-14	2010-06-29	Gregg Feinerman	Prevention and treatment of ocular side effects with a cyclosporin
CN101677987A (zh) *	2007-06-22	2010-03-24	赛多斯有限责任公司	不含吐温80的多西他赛的增溶制剂
US20090111736A1 (en) *	2007-10-29	2009-04-30	Sri International	Orally-Absorbed Solid Dose Formulation for Vancomycin
CN101559059B (zh) *	2008-04-16	2012-12-05	北京万全阳光医学技术有限公司	一种含有盐酸阿米洛利的药物组合物及其制备方法
US20090318561A1 (en) *	2008-06-23	2009-12-24	Mutual Pharmaceutical Company, Inc.	Colchicine products, method of manufacture, and methods of use
EP2323631A1 (de) *	2008-08-07	2011-05-25	Schering Corporation	Pharmazeutische formulierungen eines hcv-proteasehemmers in einer festen molekularen dispersion
US7820681B1 (en)	2009-01-14	2010-10-26	Mutual Pharmaceutical Company, Inc.	Methods for concomitant administration of colchicine and a second active agent
US20110046228A1 (en) *	2009-08-20	2011-02-24	Mutual Pharmaceutical Company, Inc.	Methods for administration of colchicine with grapefruit juice
US8912228B2 (en)	2009-10-19	2014-12-16	Scidose Llc	Docetaxel formulations with lipoic acid
US20110092579A1 (en) *	2009-10-19	2011-04-21	Scidose Llc	Solubilized formulation of docetaxel
US7772274B1 (en)	2009-10-19	2010-08-10	Scidose, Llc	Docetaxel formulations with lipoic acid
US8541465B2 (en) *	2009-10-19	2013-09-24	Scidose, Llc	Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US20110142889A1 (en) *	2009-12-16	2011-06-16	Nod Pharmaceuticals, Inc.	Compositions and methods for oral drug delivery
JP5824511B2 (ja)	2010-05-03	2015-11-25	テイコクファーマユーエスエーインコーポレーテッド	非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
US20120295932A1 (en) *	2011-05-17	2012-11-22	Western Connecticut Health Network, Inc.	Method for the treatment of cancer
JO3685B1 (ar)	2012-10-01	2020-08-27	Teikoku Pharma Usa Inc	صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
TWI715636B (zh)	2015-09-30	2021-01-11	香港商慧源香港創新有限公司	口服紫杉烷組合物及方法
CN107843966B (zh)	2016-09-18	2021-05-04	中芯国际集成电路制造(上海)有限公司	用于装配微透镜阵列组件的方法和系统
CN106822085B (zh) *	2016-12-17	2020-03-17	浙江省人民医院	表达trail的溶瘤腺病毒联合槲皮素在抑制肝癌癌细胞增殖中的用途
TWI833710B (zh)	2017-10-06	2024-03-01	香港商慧源香港創新有限公司	高單位含量口服型紫杉烷組合物及方法
CN112351779A (zh) *	2018-04-13	2021-02-09	慧源医疗有限公司	用于治疗血管肉瘤的口服给药紫杉醇和P-gp抑制剂的治疗组合
KR20210099022A (ko) *	2018-11-21	2021-08-11	엘리바 테라퓨틱스, 인크.	약제학적 방법

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5118493A (en)	1986-05-02	1992-06-02	Brigham And Women's Hospital	Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine
ATE95193T1 (de)	1987-06-17	1993-10-15	Sandoz Ag	Cyclosporine und deren benutzung als arzneimittel.
CA1340821C (en) *	1988-10-06	1999-11-16	Nobuyuki Fukazawa	Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
JP2525478B2 (ja)	1989-03-01	1996-08-21	帝人株式会社	安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤
US4960790A (en) *	1989-03-09	1990-10-02	University Of Kansas	Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5114951A (en)	1989-04-11	1992-05-19	Burroughs Wellcome Company	Agents for combating multiple drug resistance
GB8914060D0 (en)	1989-06-19	1989-08-09	Wellcome Found	Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5208238A (en)	1989-06-19	1993-05-04	Burroughs Wellcome Company	Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
GB8914040D0 (en)	1989-06-19	1989-08-09	Wellcome Found	Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914062D0 (en)	1989-06-19	1989-08-09	Wellcome Found	Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914061D0 (en)	1989-06-19	1989-08-09	Wellcome Found	Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8926715D0 (en)	1989-11-28	1990-01-17	Haessle Ab	Improvements relating to the administration of pharmaceutical agents
DE69120430D1 (de)	1990-12-18	1996-07-25	Wellcome Found	Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
SK280864B6 (en)	1991-01-11	2000-08-14	Laboratoires Glaxo Sa	Acridine derivatives, process for their preparation, and pharmaceutical compositions based thereon
US5166207A (en)	1991-06-17	1992-11-24	Neurotherapeutics, Inc.	Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
FR2678833B1 (fr) *	1991-07-08	1995-04-07	Rhone Poulenc Rorer Sa	Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5750561A (en)	1991-07-08	1998-05-12	Rhone-Poulenc Rorer, S.A.	Compositions containing taxane derivatives
CA2149150C (en)	1992-11-27	2000-08-01	David R. Carver	Injectable taxol composition with improved stability
FR2698543B1 (fr)	1992-12-02	1994-12-30	Rhone Poulenc Rorer Sa	Nouvelles compositions à base de taxoides.
US5646176A (en)	1992-12-24	1997-07-08	Bristol-Myers Squibb Company	Phosphonooxymethyl ethers of taxane derivatives
US6096331A (en)	1993-02-22	2000-08-01	Vivorx Pharmaceuticals, Inc.	Methods and compositions useful for administration of chemotherapeutic agents
US5387685A (en)	1993-07-16	1995-02-07	American Cyanamid Co	MDR reversal agents
CA2129288C (en) *	1993-08-17	2000-05-16	Jerzy Golik	Phosphonooxymethyl esters of taxane derivatives
TW406020B (en) *	1993-09-29	2000-09-21	Bristol Myers Squibb Co	Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5610173A (en) *	1994-01-07	1997-03-11	Sugen, Inc.	Formulations for lipophilic compounds
US5567592A (en)	1994-02-02	1996-10-22	Regents Of The University Of California	Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5565478A (en) *	1994-03-14	1996-10-15	The United States Of America As Represented By The Department Of Health & Human Services	Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
FR2718963B1 (fr)	1994-04-25	1996-05-24	Rhone Poulenc Rorer Sa	Nouvelle composition pharmaceutique à base de taxoïdes.
US5616330A (en) *	1994-07-19	1997-04-01	Hemagen/Pfc	Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
US5681846A (en) *	1995-03-17	1997-10-28	Board Of Regents, The University Of Texas System	Extended stability formulations for paclitaxel
US5716928A (en) *	1995-06-07	1998-02-10	Avmax, Inc.	Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5665386A (en) *	1995-06-07	1997-09-09	Avmax, Inc.	Use of essential oils to increase bioavailability of oral pharmaceutical compounds
GB9514878D0 (en) *	1995-07-20	1995-09-20	Danbiosyst Uk	Vitamin E as a solubilizer for drugs contained in lipid vehicles
US6395770B1 (en) *	1995-10-26	2002-05-28	Baker Norton Pharmaceuticals, Inc.	Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) *	1995-10-26	2001-06-12	Baker Norton Pharmaceuticals, Inc.	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5968972A (en) *	1995-10-26	1999-10-19	Baker Norton Pharmaceuticals, Inc.	Method for increasing the oral bioactivity of pharmaceutical agents
CA2221444A1 (en)	1996-01-31	1997-08-07	Steven B. Hansel	A method of making pharmaceutically active taxanes orally bioavailable
US5877205A (en) *	1996-06-28	1999-03-02	Board Of Regents, The University Of Texas System	Parenteral paclitaxel in a stable non-toxic formulation
US6458373B1 (en) *	1997-01-07	2002-10-01	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
IL131217A0 (en) *	1998-03-10	2001-01-28	Napro Biotherapeutics Inc	Novel methods and compositions for delivery of taxanes
US6136846A (en) *	1999-10-25	2000-10-24	Supergen, Inc.	Formulation for paclitaxel

1996
- 1996-10-16 US US08/733,142 patent/US6245805B1/en not_active Expired - Fee Related
- 1996-10-24 PL PL96321791A patent/PL188281B1/pl not_active IP Right Cessation
- 1996-10-24 DE DE69636531T patent/DE69636531T2/de not_active Expired - Fee Related
- 1996-10-24 SK SK859-97A patent/SK85997A3/sk unknown
- 1996-10-24 PL PL368566A patent/PL192544B1/pl unknown
- 1996-10-24 CN CNB031458033A patent/CN100335123C/zh not_active Expired - Fee Related
- 1996-10-24 WO PCT/IB1996/001485 patent/WO1997015269A2/en not_active Ceased
- 1996-10-24 EP EP96943268A patent/EP0794794B1/de not_active Expired - Lifetime
- 1996-10-24 CN CN96191685A patent/CN1119146C/zh not_active Expired - Fee Related
- 1996-10-24 CZ CZ972028A patent/CZ202897A3/cs unknown
- 1996-10-24 AT AT96943268T patent/ATE311903T1/de not_active IP Right Cessation
- 1996-10-24 NZ NZ324801A patent/NZ324801A/xx unknown
- 1996-10-24 BR BR9607066-8A patent/BR9607066A/pt not_active Application Discontinuation
- 1996-10-24 DK DK96943268T patent/DK0794794T3/da active
- 1996-10-24 MX MX9704629A patent/MX9704629A/es not_active IP Right Cessation
- 1996-10-24 AU AU12056/97A patent/AU698142B2/en not_active Ceased
- 1996-10-24 ES ES96943268T patent/ES2109899T3/es not_active Expired - Lifetime
- 1996-10-24 DE DE0794794T patent/DE794794T1/de active Pending
- 1996-10-24 RU RU97112888/14A patent/RU2217135C2/ru not_active IP Right Cessation
- 1996-10-24 CA CA002205534A patent/CA2205534A1/en not_active Abandoned
- 1996-10-24 JP JP51644997A patent/JP3361102B2/ja not_active Expired - Fee Related
- 1996-10-24 IL IL12116096A patent/IL121160A0/xx unknown
- 1996-10-24 HU HU9900457A patent/HUP9900457A3/hu unknown
1997
- 1997-06-25 NO NO19972968A patent/NO321091B1/no unknown
2001
- 2001-04-10 US US09/829,846 patent/US6610735B2/en not_active Expired - Fee Related
2002
- 2002-09-12 US US10/242,050 patent/US6818615B2/en not_active Expired - Fee Related
2004
- 2004-03-15 US US10/800,990 patent/US7041640B2/en not_active Expired - Fee Related
2005
- 2005-04-13 US US11/105,081 patent/US20050238634A1/en not_active Abandoned
2006
- 2006-08-14 US US11/503,607 patent/US20070060635A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NZ324801A (en)	1999-05-28
WO1997015269A2 (en)	1997-05-01
CN1173817A (zh)	1998-02-18
US6245805B1 (en)	2001-06-12
US20070060635A1 (en)	2007-03-15
SK85997A3 (en)	1998-06-03
JPH10509741A (ja)	1998-09-22
ES2109899T1 (es)	1998-02-01
NO972968L (no)	1997-07-23
AU698142B2 (en)	1998-10-22
US20050238634A1 (en)	2005-10-27
NO972968D0 (no)	1997-06-25
PL188281B1 (pl)	2005-01-31
DE69636531T2 (de)	2006-12-07
ES2109899T3 (es)	2006-05-01
US20020058616A1 (en)	2002-05-16
HK1001960A1 (en)	1998-07-24
MX9704629A (es)	1997-09-30
US7041640B2 (en)	2006-05-09
US20040176439A1 (en)	2004-09-09
DE794794T1 (de)	1998-03-12
NO321091B1 (no)	2006-03-13
EP0794794A1 (de)	1997-09-17
US6818615B2 (en)	2004-11-16
DK0794794T3 (da)	2006-04-18
US6610735B2 (en)	2003-08-26
US20030069301A1 (en)	2003-04-10
CN1119146C (zh)	2003-08-27
CN100335123C (zh)	2007-09-05
PL192544B1 (pl)	2006-11-30
EP0794794A4 (de)	2000-03-01
AU1205697A (en)	1997-05-15
IL121160A0 (en)	1997-11-20
HUP9900457A2 (hu)	1999-06-28
RU2217135C2 (ru)	2003-11-27
CA2205534A1 (en)	1997-05-01
PL321791A1 (en)	1997-12-22
WO1997015269A3 (en)	1997-07-31
EP0794794B1 (de)	2005-12-07
CN1490048A (zh)	2004-04-21
BR9607066A (pt)	2002-12-10
JP3361102B2 (ja)	2003-01-07
CZ202897A3 (cs)	1998-03-18
DE69636531D1 (de)	2006-10-19
HUP9900457A3 (en)	2001-04-28

Legal Events

Date

Code

Title

Description

2006-09-15

UEP

Publication of translation of european patent specification

Ref document number: 0794794

Country of ref document: EP

2009-07-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69636531D1 (de)	2006-10-19	Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
BG101118A (en)	1998-04-30	Therapeutical compounds
DE69713526D1 (de)	2002-07-25	Lösliche prodrugs von paclitaxel
ATE264671T1 (de)	2004-05-15	Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
MXPA04000920A (es)	2004-04-02	Derivados de aminoisoxazol activos como inhibidores de la cinasa.
DE60311567D1 (de)	2007-03-22	Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
ATE308327T1 (de)	2005-11-15	Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
CO5251419A1 (es)	2003-02-28	Composiciones nanoparticuladas de eplerenona
HUP0104795A2 (hu)	2002-04-29	CCR5 modulátor hatású azabicikloalkán vegyületek, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
EE04800B1 (et)	2007-04-16	Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks
IL112664A0 (en)	1995-05-26	4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
BR0314797A (pt)	2005-07-26	Derivados da pirimidineamida e o uso dos mesmos
ATE292453T1 (de)	2005-04-15	Antivirale arznei
DE60215313D1 (de)	2006-11-23	Indolderivate und deren verwendung als gnrh antagonisten
DE69824313D1 (de)	2004-07-08	Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
ATE198278T1 (de)	2001-01-15	Verwendung von sulodexid und von arzneimitteln, die dieses enthalten, zur behandlung der diabetischen nephropathie
DE60030283D1 (de)	2006-10-05	Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
RU94040886A (ru)	1996-09-20	Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
ATE331523T1 (de)	2006-07-15	Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
IL112668A0 (en)	1995-05-26	4-amino 6-substituted mycophenolic acid and derivatives thereof, their preparation and pharmaceutical compositions containing them
ATE293445T1 (de)	2005-05-15	Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
RU95102147A (ru)	1996-12-10	Производные 1-[2-(1н-инден-3-ил)этил]-4-(нафт-1-ил)пиперазина, способ их получения и содержащие их медикамент и фармацевтический состав
TH58669A (th)	2003-09-30	ยารวมที่ประกอบด้วยเมอร์ทาซาพีนสำหรับการรักษาโรคซึมเศร้าและความผิดปกติต่างๆที่เกี่ยวข้องกัน
MD940244A (ro)	1996-01-31	Derivaţi noi ai tetrazolului, procedeu de obţinere a lor şi compoziţie farmaceutică pe baza lor